GAK is the major therapeutic target of Parkinson's disease and novel chemicals that inhibit its kinase activity are currently being developed [35]; gefitinib and luteolin may also be clinically useful for the treatment of prostate cancer and osteosarcoma. Here, GAK is linked to Parkinson disease.